IPP Bureau
Vimta Labs Q1 FY26 PAT climbs to Rs. 18.89 Cr
By IPP Bureau - July 18, 2025
Vimta Labs has reported total income of Rs. 99.31 crores during the period ended June 30, 2025
Zigly launches its first pet hospital in Mumbai
By IPP Bureau - July 18, 2025
The new Zigly center features and offers comprehensive veterinary services
Kenvue collaborates with API to launch India’s first cough clinics
By IPP Bureau - July 18, 2025
Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough
Brenntag Specialties Pharma offering phosphate-based excipients by Budenheim
By IPP Bureau - July 18, 2025
Phosphate-based excipients provide higher bulk densities and enable the reduction of the tablet sizes
Lupin receives Form 483 with 4 observations from USFDA for Pithampur unit-2
By IPP Bureau - July 18, 2025
The company is addressing these observations comprehensively
Concord Biotech announces successful completion EU GMP inspection at its API facility
By IPP Bureau - July 18, 2025
This achievement underscores our unwavering commitment to upholding the highest standards of quality, safety, and regulatory compliance
Shilpa Medicare receives EIR from USFDA for Unit VI, Bengaluru
By IPP Bureau - July 17, 2025
This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms
SMS Lifesciences India receives EIR with VAI status from USFDA for API facility at Kazipally
By IPP Bureau - July 17, 2025
The receipt of EIR reaffirms the company's commitment to maintaining global quality standards
Lupin launches Loteprednol Etabonate ophthalmic suspension 0.5% in US
By IPP Bureau - July 17, 2025
Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva
Suven Life Sciences announces first patient randomized in Phase-2b clinical trial of Ropanicant
By IPP Bureau - July 17, 2025
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
Corona Remedies acquires 7 brands from Bayer's pharma division in India
By IPP Bureau - July 17, 2025
This marks the fourth acquisition by Corona Remedies from multinational corporations
Thermo Fisher Scientific to acquire Sanofi’s steriles manufacturing site in Ridgefield, New Jersey
By IPP Bureau - July 17, 2025
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
